Mouse models have revealed that oncogenic Kras can act as a “master regulator” of PDA development, establishing lineages that can give rise to PanINs and PDA and remaining critical for progression[1], [2], [3]. This evidence concerns the gene KRAS and Patent ductus arteriosus.